Bovine Mastitis Market Size, Share & COVID-19 Impact Analysis, By Type (Clinical, and Sub-Clinical), By Product (Antibiotics, and Others), By Route of Administration (Intramammary, and Systemic), By Therapy (Lactating Period and Dry Period {Antibiotics, and Others}) and Regional Forecast, 2020-2027

The global bovine mastitis market size was valued at USD 1.23 billion in 2019 and is projected to reach USD 1.84 billion by 2027, exhibiting a CAGR of 5.2% during the forecast period.

Globally, with the rise in number of dairy herds, the incidence of bovine mastitis is rising rapidly every year. According to the Cornell University College of Veterinary Medicine, the global incidence of clinical mastitis is approximately 0 to 200 cases per 100 cows annually. Various regional studies have narrowed down the estimated incidence of clinical mastitis in the range of 25 to 30 cases per 100 cows annually. This rising incidence is resulting in significant economic loss to dairy industry in terms of lower milk production, reduced milk quality, and leading to high cost of bovine mastitis treatment. According to the research published by the University of Glasgow, mastitis is estimated to cost around USD 19.7 billion to USD 30.0 billion to the global dairy industry annually.  

Several market players are strongly focusing on collaborations to accelerate research and development activities for the introduction of novel products for mastitis control. For instance, in 2019 Zoetis signed an agreement with and Colorado State University (CSU), U.S., to establish a research lab in order to explore new livestock immunotherapies including mastitis therapeutics.

Covid-19 Pandemic to have a Minimal Impact on Dairy Industry and Subsequently the Global Market

The COVID-19 outbreak did not have any significant impact on the uptake of products for the treatment of bovine mastitis. According to the report published by Zoetis in April 2020, there has been no direct impact on the supply chain of the products and various companies are in close contact with the US FDA in order to keep them informed about the shortage or delays in the production.

Moreover, many animal healthcare associations such as AnimalhealthEurope and various national authorities are working collectively to maintain an extensive network of transport services, through implementation of the green lanes under the guidelines for border management measures to protect health and ensure the availability of goods and essential services including veterinary medicines.

LATEST TRENDS

Request a Free sample to learn more about this report.

Shifting Focus towards Non-antibiotics for Treatment

Globally, dairy cattle farmers are demanding effective treatment for the fatal mammary gland infection in the cattle. The rising economic burden on dairy cattle farmers and the increase in the antibiotic resistance pathogens is diverting the focus of many biopharmaceutical companies towards the development of non-antibiotic treatment for the condition.

For instance, Westway Health - an Ireland based company has been working towards the development of product PanaMast, a novel non-antibiotic therapy that is anticipated to provide a much needed non-antibiotic approach for the treatment. The growing awareness among dairy farms globally regarding antibiotic resistance, is also pushing the demand for novel approaches and products for treatment of the condition. Thus, such research initiatives towards the introduction of novel therapies by market players are likely to drive the demand for drugs in treatment during the forecast period.

DRIVING FACTORS

Increasing Incidence is likely to Accelerate Market Growth

Bovine mastitis has become one of the serious concerns in the dairy industries across the globe. The dairy farmers are facing high monetary losses with the rise in the incidence of this cases in cattle every year. For instance, according to the research article published by the Journal of Dairy Science in 2017, 31 cases of clinical mastitis were reported in 100 cows per year in U.S. dairy herds. The cost was around USD 350 to USD 500 per case.

This includes direct and indirect costs such as diagnostics, milk loss, veterinary services, labor, future milk production losses, and therapeutics, among others. The direct losses due to clinical mastitis are lower, as compared to indirect losses. Also, according to various regional and national estimates, an estimated 10% - 12% of total cost of mastitis per case, is associated with therapeutics.

The rise in the incidence of the disease among bovine animals and growing awareness among dairy farmers regarding treatment is fueling the demand for antibiotics in treatment of the condition. This is further augmented by the introduction of non-antibiotic drugs by market players, for bovine mastitis treatment. 

Introduction of New Products for the Treatment to Provide Lucrative Growth to the Market

Novel developments are anticipated to have a huge impact on this market. Many veterinary companies are currently emphasizing on the launch of new products. Market players are entering into strategic mergers, partnerships, and acquisitions to leverage a synergistic effect, and accelerate the development of new products to prevent the increasing incidence of mastitis. For instance, in February 2020, Merck & Co., Inc. announced the launch of Shut Out, a new teat sealant which is an antibiotic-free intramammary paste, specifically intended to aid in the prevention of intramammary infections including mastitis in cattle. These new product introductions are anticipated to fill the clinical gap currently posed by the antibiotics, and other drugs for efficient treatment of mastitis.

RESTRAINING FACTORS

Increase in Antibiotic Resistance Pathogen and Lack of Awareness about Mastitis Disease to Restrict the Market Growth

Mastitis is the one of most prevalent bacterial diseases of dairy cattle across the globe. The prolonged usage of antibiotics for treatment of mastitis, has led to rise in increase in antimicrobial resistance (AMR) among the pathogens causing the infectious disease. The rise in number of multi-resistant strains has reduced the effectiveness of the antibiotics, rendering the treatment complicated, costly, and time consuming. This, combined with limited availability of non-antibiotic drugs, is limiting the demand for antibiotics, further hampering the market growth.

Moreover, there has been a lack of awareness about the disease among dairy farmers in many emerging nations. In addition to this, the limited availability of drugs due to weak supply chain of major players in rural areas, is another major factor restricting the bovine mastitis market growth.

SEGMENTATION

By Type Analysis

Increase in the Incidence of Clinical Mastitis has led to the Dominance of the Segment

Based on type, the market is segmented into clinical and sub-clinical. The considerable increase in the dairy herd size and growing number incidence cases of clinical mastitis in dairy cattle farms in both developed and emerging nations are the factors anticipated for the dominance of the clinical mastitis segment during the forecast period.

For instance, according to a study conducted in 41 herds and 458 dairy cows in Canada by the Canadian Bovine Mastitis Research Network (CBMRN), the incidence of clinical mastitis was found to be around 26.3 cases per 100 cows. The urgent need for treatment of clinical mastitis, combined with availability of drugs, and growing awareness, are leading to a wider adoption globally.

The sub-clinical segment is anticipated to project a significant CAGR during the forecast period owing to the rising awareness among cattle farmers regarding the difficulty in detection of subclinical mastitis and the need for the early treatment of subclinical mastitis.

By Product Analysis

Clinical Efficiency of Antibiotics Segment has led to Higher Preference among End Users

On the basis of product, the market segments include antibiotics and others. The antibiotics segment held a dominant bovine mastitis market share of the global market in 2019. Antibiotics are the standard products for treatment due to the limited presence of other class of drugs for the treatment of mastitis, making large number of dairy farms to prefer antibiotics for the treatment.  Moreover, antibiotics have shown clinical effectiveness towards the control of mastitis in dairy cattle, subsequently driving the preference of veterinary health providers towards this drug class.

The others segment is projected to register a higher CAGR by 2027 due to the increased focus on the launch of innovative treatment products by the key players and various effective therapies in pipeline.

By Route of Administration Analysis

Higher clinical Effectiveness of Intramammary Route is Boosting the Adoption

In terms of route of administration, the market is segmented into intramammary and systemic. The intramammary segment held the highest market share and is register a significant growth by the end of forecast period.  This is due to the presence of large number of intramammary products for the treatment, and clinical effectiveness of intramammary route of administration over systemic route of administration.

By Therapy Analysis

To know how our report can help streamline your business, Speak to Analyst

Growing Awareness Regarding Infections during Dry-off Period to Boost the Demand for Products

In terms of therapy, the market is segmented into lactating period and dry period and systemic. The dry period segment held the highest market share and is register a significant growth by the end of forecast period.  The strong awareness about the rise in the number of the mastitis infection in bovine has led to an increase in the demand for effective treatment therapy during the dry period. Moreover, the growing shift towards the use of selective dry cow therapy has led to a decrease in the usage of intramammary antibiotics and increase in the adoption of internal teat sealants at drying-off.

Additionally, an increased focus on the launch of teat sealant and initiatives taken by players in promoting the adoption of teat sealants among dairy farmers are anticipated to boost the demand for teat sealants during the dry period to prevent mastitis infection. For instance, in March 2020, Jurox Pty Limited announced the launch of, a non-antibiotic dry cow intra-mammary teat sealant, U-Seal for Australian framers

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

The bovine mastitis market size in North America stood at USD 0.40 billion in 2019. The dominance of this region is attributable to the strong adoption of intramammary infusion products for the treatment, and the presence of leading players in the region offering wide range of products for the mastitis control. The market in Europe is expected to grow at a significant CAGR owing Increase in the collaboration among key players in the region to launch innovative product for curing mastitis.

The market in Asia Pacific is expected to exhibit fastest growth owing to the large population of cattle and increase in the incidence of bovine mastitis annually. For instance, according to the Department of Animal Husbandry & Dairying (DAHD) bovine population in India is 302.79 Million in 2019.  

Moreover, the rising economic burden on farmers with the rising prevalence of subclinical mastitis over clinical mastitis in anticipated to propel the growth of the market in this region.  For instance, according to the research article published in the World Journal of Pharmaceutical and Medical Research (WJPMR) journal in 2017, in India out of annual economic loss, approximately 70% -80% of the loss was associated with sub-clinical mastitis infections. Along with this, higher adoption of intramammary products and rise in initiatives undertaken by government to implement guidelines on the use of intramammary products, will fuel demand for products used for bovine mastitis treatment in the Asia Pacific.

Market in Latin America, and Middle East & Africa is in the nascent stages. However, growing animal husbandry industry in these countries, along with establishment of animal health organizations at a regional and country level, will boost the growth of the market in these regions.

KEY INDUSTRY PLAYERS

Strong Product Portfolio has Propelled Merck & Co., Inc., Zoetis, and Boehringer Ingelheim International GmbH to Lead the Market

The bovine mastitis market is consolidated owing to the wide range of product offering and robust distribution network of major companies in developed and emerging nations. Currently, Merck & Co., Inc., Zoetis, and Boehringer Ingelheim International GmbH, account for a dominant share. Factors such as large manufacturing sites and strong focus on introduction of innovative products for treatment of mastitis diseases are expected to maintain its position in the market

Other key players such as Elanco, Ceva, Bayer AG, West Way Health, and others are planning to strengthen their foothold in the market by adopting various strategies such as emphazing on investment in development of novel therapies, such as biological therapies for the treatment and collaborations with the research organizations and other key players.

LIST OF KEY COMPANIES PROFILED:

• Zoetis (New Jersey, U.S.)                             


• Merck & Co., Inc. (MSD Animal Health)   (New Jersey, U.S.)                          


• Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany)                          


• Bayer AG (Leverkusen, Germany)


• Elanco (Indiana, U.S.)


• Ceva (Libourne, France)                                                                          


• West Way Health (Galway, Ireland)


• Others

KEY INDUSTRY DEVELOPMENTS:

• April 2021 - Boehringer Ingelheim, a worldwide leader in animal health, announced to add blue Ubroseal internal teat sealant to its dairy mastitis portfolio to prevent new intramammary infections during the dry period.


• October 2020 – NovaQues collaborated with Mileutis and signed a USD 20 million peptide product development deal. Mileutis also announced to launch its peptide product Imilac to market, which will be used to manage, treat, and prevent bovine mastitis.


• February 2020 - Ecolab Inc. announced the launch of Eco-Flex Teat Dip, an affordable udder care solution for dairy cows to prevent disinfecting, condition teat skin, and support milk quality. It is available through Ecolab agricultural products distributors.

REPORT COVERAGE

An Infographic Representation of Bovine Mastitis Market

View Full Infographic

To get information on various segments, share your queries with us

The bovine mastitis market report provides a detailed analysis of the market and focuses on key aspects such as leading companies, product types for treatment, and advantages of the product. Besides this, the report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over the recent years.

Report Scope & Segmentation